Paediatric schistosomiasis: What we know and what we need to know

by Derick N. M. Osakunor, Mark E. J. Woolhouse, Francisca Mutapi
PLoS Negl Trop Dis 12(2): e0006144 – February 8, 2018

16 pp. 2.7 MB
http://journals.plos.org/plosntds/article/file?
id=10.1371/journal.pntd.0006144&type=printable

Schistosomiasis affects over 200 million people worldwide, most of whom are children. Research and control strategies directed at preschool-aged children (PSAC), i.e., ≤5 years old, have lagged behind those in older children and adults. With the recent WHO revision of the schistosomiasis treatment guidelines to include PSAC, and the recognition of gaps in our current knowledge on the disease and its treatment in this age group, there is now a concerted effort to address these shortcomings. The authors highlight risk factors, immune mechanisms, pathology, and optimal timing for screening, diagnosis, and treatment of paediatric schistosomiasis. They also discuss the tools required for treating schistosomiasis in PSAC and strategies for accessing them for treatment.

(Visited 19 times, 1 visits today)
This entry was posted in General, Maternal & Child Health, Other Infectious Diseases. Bookmark the permalink.